ライフサイエンスコーパス: and every * weeks thereafter

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 , 24 weeks, and 32 weeks of treatment from day 1 of cycle 1 and every 12 weeks thereafter.

2 Response to treatment was assessed at week 12 and every 8 weeks thereafter.

3 fliximab (5 mg/kg of body weight) at weeks 1, 3, 7, and 14, and every 8 weeks thereafter.

4 -to-treat population, assessed every 6 weeks until month 18 and every 9 weeks thereafter.

5 ity-of-life instrument at baseline, weeks 4, 7, 10, and 24, and every 12 weeks thereafter up to 2 years, irrespective of

6 4 weeks and FPG was measured at baseline, week 12, week 24, and every 24 weeks thereafter, and potential cases of new-ons

7 received ustekinumab 45 mg, which they continued at week 28 and every 12 weeks thereafter.

8 ramuscularly on day 1, followed by 250 mg on days 15 and 28 and every 4 weeks thereafter, and either lapatinib 1,500 mg o

9 V abatacept ( approximately 10 mg/kg) on days 1, 15, and 29 and every 4 weeks thereafter.

10 hereafter, 100 mg every 8 weeks, or 200 mg at weeks 0 and 4 and every 12 weeks thereafter) through week 40, placebo, or a

11 eks thereafter, 15 mg every 8 weeks, 50 mg at weeks 0 and 4 and every 12 weeks thereafter, 100 mg every 8 weeks, or 200 m

12 domly assigned to receive guselkumab (5 mg at weeks 0 and 4 and every 12 weeks thereafter, 15 mg every 8 weeks, 50 mg at

13 y in week 1 (10(6) plaque-forming units/mL), then in week 4 and every 2 weeks thereafter (10(8) plaque-forming units/mL).

14 Safety was assessed at weeks 2 and 4 and every 4 weeks thereafter; tumor response was evaluated ev

15 tekinumab, 90 mg ustekinumab, or placebo at week 0, week 4, and every 12 weeks thereafter.

16 or 1.5 mg BHT-3009, given intramuscularly at weeks 0, 2, 4, and every 4 weeks thereafter until week 44.

17 Study visits were at baseline, weeks 2 and 4, and every 4 weeks thereafter.

18 ximab or placebo infusions were given at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46.

19 ssay in available samples at baseline (b; n = 472), week 9, and every 12 weeks thereafter.

20 ploratory endpoint, PROs were assessed at baseline, week 9, and every 6 weeks thereafter using the European Organisation

21 by 3-day weighed food records) will be measured at baseline and every 4 weeks thereafter.

22 , weight, and waist circumference were measured at baseline and every 4 weeks thereafter.

23 pia Treatment Study HOTV visual acuity protocol at baseline and every 9 weeks thereafter until no further improvement in

24 remelimumab (10 mg/kg) or placebo every 4 weeks for 7 doses and every 12 weeks thereafter until a treatment discontinuati

25 23 mice (7 L1, 8 L2, 8 LC) were scanned at 1 month of life and every 4 weeks thereafter.

26 Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter.

27 nsgenic (non-Tg) controls at 6-8 weeks of age (pre-plaque), and every 2 weeks thereafter until all mice were at least 16

28 ring the study for the first 12 months after randomisation, and every 12 weeks thereafter until study drug discontinuatio

29 ollow-up was every 3 weeks to 21 weeks after randomisation, and every 8 weeks thereafter.

30 nd the intention-to-treat population, assessed at screening and every 12 weeks thereafter.

31 ously within 24 hours after cardiac-transplantation surgery and every two weeks thereafter, for a total of five doses, or

32 Follow-up blood cultures were obtained routinely at 4 weeks and every 8 weeks thereafter.

33 Courses were repeated at 4 and 8 weeks, and every 5 weeks thereafter.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。